Patients with known symptomatic central nervous system metastases requiring steroids.
Symptomatic central nervous system metastases
Known active uncontrolled or symptomatic Central Nervous System (CNS) metastases
Participants with symptomatic central nervous system (CNS) metastases who are neurologically unstable and/or require radiation therapy are excluded;\r\n* Participants with brain metastases that do not meet the above criteria in the opinion of the treating investigator \r\n* Symptomatic disease is allowed as long as symptoms are controlled and stable
Symptomatic central nervous system (CNS) metastases.
Patients with symptomatic central nervous system (CNS) metastases who are neurologically unstable
Symptomatic central nervous system metastases
Known active uncontrolled or symptomatic Central Nervous System (CNS) metastases.
Presence of symptomatic or uncontrolled central nervous system or leptomeningeal metastases
Subjects with symptomatic Central Nervous System (CNS) metastases
Untreated central nervous system metastatic disease, leptomeningeal disease, or cord compression; subjects previously treated central nervous system metastases that are radiographically and neurologically stable for at least  weeks and do not require corticosteroids (of any dose) for symptomatic management for at least  days prior to first dose of MEDI and tremelimumab are permitted to enroll
Individuals with the presence of symptomatic central nervous system (CNS) metastases requiring radiation treatment, surgery, or ongoing use of corticosteroids
Presence of untreated or symptomatic central nervous system metastases, or central nervous system metastases that currently require local therapy (such as radiotherapy or surgery), or require doses of corticosteroids within the prior  weeks
Symptomatic central nervous system metastases
Presence of symptomatic or uncontrolled central nervous system (CNS) metastases requiring local CNS-directed treatment.
Symptomatic central nervous system (CNS) metastases who are neurologically unstable
Evidence of progressive or symptomatic central nervous system (CNS) metastases or leptomeningeal disease
Patients with symptomatic central nervous system (CNS) metastases.
Presence of symptomatic central nervous system (CNS) metastases
Symptomatic central nervous system (CNS) metastases requiring treatment
Central nervous system (CNS) metastases that are symptomatic and/or requiring steroids
Known symptomatic central nervous system (CNS) metastases
Symptomatic central nervous system metastases (excluding Glioblastoma multiforrme (GBM) and Primary Central Nervous System Lymphoma (PCNSL). Subjects with brain metastases that have been previously treated and are stable for  weeks are allowed.
Patients with a history of symptomatic central nervous system metastases, unless treated and asymptomatic
Symptomatic central nervous system metastases; subjects with brain metastases that have been previously treated and are stable for  weeks are allowed
Presence of symptomatic or uncontrolled brain or central nervous system metastases
Central nervous system metastases unless: () metastases have been treated and have remained controlled for at least two weeks following treatment, AND () patient has no residual neurological dysfunction off corticosteroids for at least one week; a CT or MRI to evaluate for central nervous system (CNS) disease is required for symptomatic patients only
Subjects with symptomatic central nervous system (CNS) metastases
Patients with symptomatic central nervous system (CNS) metastases
Symptomatic central nervous system metastases or lesions requiring treatment.
Subjects with active or symptomatic central nervous system metastases are excluded. Subjects with central nervous system metastases are eligible for the study if the metastases have been treated by surgery and/or radiation therapy, the subject is off corticosteroids for at least  weeks and the subject is neurologically stable
Patients with known symptomatic central nervous system (CNS) metastases requiring steroids
Patient with symptomatic brain metastases, ie, not neurologically stable or requiring treatment with corticosteroids, or central nervous system (CNS) leukemia.
Symptomatic central nervous system metastases; subjects with brain metastases that have been previously treated and are stable for  weeks are allowed
Symptomatic central nervous system (CNS) metastases requiring steroid use
Patients with symptomatic central nervous system (CNS) metastases must have stable disease after treatment with surgery or radiation therapy
Symptomatic Central Nervous System (CNS) metastases
Patients with symptomatic Central Nervous System (CNS) metastases
Presence of symptomatic central nervous system metastases.
